These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 17846006)

  • 1. [Angiogenesis and breast cancer].
    Bachelot T; Ray-Coquard I; Cassier P; Blay JY
    Bull Cancer; 2007 Jul; 94 Spec No():S203-10. PubMed ID: 17846006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic agents in breast cancer.
    Salter JT; Miller KD
    Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
    [No Abstract]   [Full Text] [Related]  

  • 3. Bevacizumab for advanced breast cancer.
    Traina TA; Rugo HS; Dickler M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab in the treatment of breast cancer.
    Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
    Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    Marty M; Pivot X
    Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast tumour angiogenesis.
    Fox SB; Generali DG; Harris AL
    Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer.
    Banerjee S
    Steroids; 2011 Jul; 76(8):807-11. PubMed ID: 21439993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
    Ellis LM; Rosen L; Gordon MS
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?
    Miller KD
    Breast Cancer Res; 2004; 6(3):128-32. PubMed ID: 15084233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
    Collins TS; Hurwitz HI
    Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-angiogenic treatment and colorectal cancer].
    André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
    Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-VEGF therapy with bevacizumab in breast cancer].
    Tóth J; Gonda A; Szántó J
    Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiogenesis targeting in breast cancer].
    Fumoleau P; Coudert B; Mayer F; Isambert N; Favier L; Ferrant E
    Bull Cancer; 2007; 94(7 Suppl):F199-206. PubMed ID: 17964997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?
    Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E
    Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in the treatment of metastatic breast cancer.
    Traina TA
    Oncology (Williston Park); 2009 Apr; 23(4):327-32. PubMed ID: 19476261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Are antiangiogenic antibodies universal for solid tumor?].
    Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
    Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.